Domain > treatdlbcl.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2024-11-10	20.119.0.19 (ClassC)

Port 443

HTTP/1.1 200 OKContent-Type: text/html; charsetutf-8Date: Sun, 09 Jun 2024 21:41:24 GMTServer: nginx/1.24.0Transfer-Encoding: chunkedX-Powered-By: PHP/8.2.17

script typeapplication/ld+json>{	@context: https://schema.org/,	@type: MedicalWebPage,    url:https://www.monjuvihcp.com,   	specialty:https://health-lifesci.schema.org/Oncologic,	audience:https://health-lifesci.schema.org/Clinician,    headline: MONJUVI (tafasitamab-cxix): Treatment for R/R DLBCL | Official HCP Site,    description:MONJUVI (tafasitamab-cxix) 200 mg for injection, targeted immunotherapy for intravenous use in R/R DLBCL and recommended by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Please see the full Prescribing Information, including indication and Important Safety Information.,    mainContentOfPage:         {@type: WebPageElement,        name: MONJUVI,        text: MONJUVI is an outpatient targeted immunotherapy for adult NTE patients with R/R DLBCL in 2L.},        {@type: WebPageElement,        name: NCCN Preferred,        text: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend tafasitamab-cxix (MONJUVI) in combination with lenalidomide as a preferred second-line or subsequent therapy option (if not previously used) for DLBCL in patients who are not candidates for transplant (Category 2A).},    potentialAction:         {@type: Action,            name: See the long-term data,            url: https://www.monjuvihcp.com/efficacy},        {@type: Action,            name: 2L Treatment Factors,            url: https://www.monjuvihcp.com/treatment-factors},        {@type: Action,            name: Review the safety profile of MONJUVI,            url: https://www.monjuvihcp.com/safety},    image:         {@type: ImageObject,            name: National Comprehensive Cancer Network (NCCN) Preferred Treatment Option,            url: https://www.monjuvihcp.com/images/global/nccn-guidelines-logo-small.png},    about:         {@type: Drug,        name: MONJUVI,        nonProprietaryName: tafasitamab-cxix,        isProprietary: True,        isAvailableGenerically: False,        dosageForm: Infusion,        administrationRoute: Infusion,        offers: {            @

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > treatdlbcl.com

Is this malicious?

DNS Resolutions

Port 443